Neilos S.R.L.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 15, 2027The maintenance fee for Composition for gastric and oesophageal diseases (US 11,723,939) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Mar 19, 2027The maintenance fee for Composition for the treatment of constipation (US 11,759,493) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Composition for the treatment of metabolic and mechanical neuropathies (US 11,918,617) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,471,501 | Pharmaceutical composition for use in the treatment of prostate pathologies In force · From the USPTO record | In force | From the USPTO record | |
| US 11,918,617 | Composition for the treatment of metabolic and mechanical neuropathies In force · From the USPTO record | In force | From the USPTO record | |
| US 11,723,939 | Composition for gastric and oesophageal diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 11,590,166 | Composition for the Treatment of Gastrointestinal Disorders In force · High confidence | In force | High confidence | |
| US 11,759,493 | Composition for the treatment of constipation In force · From the USPTO record | In force | From the USPTO record | |
| US 11,576,926 | A Composition for Use in the Prevention and/or Treatment of Epistaxis In force · High confidence | In force | High confidence | |
| US 12,636,330 | Composition for the Treatment of Skin and Mucous Membrane Diseases In force · High confidence | In force | High confidence | |
| US 12,636,313 | Nutraceutical or Pharmaceutical Composition Comprising Iron Pyrophosphate for Treating And/Or Preventing Iron Deficiency Conditions or Diseases In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 6 no status recorded